

Suprachoroidal CLS-TA Improves Patient Outcomes in Uveitis of All Anatomic Subtypes: Results of the Phase 3 PEACHTREE Study

Ron Neumann, MD
Co-Chairperson **ISOPT Clinical**
Ocular Drug Development Expert
Specializing in Inflammatory Eye Diseases

Financial Disclosures:

- Clearside Biomedical
- Orasis
- Tarsius
- Biolight
- OPh-Rx
- Novaliq
- TopiVert


EU RETINA
Paris, France
September 5-8, 2019



PEACHTREE
CLS1001-301

PEACHTREE: Phase 3, Randomized, Controlled, Double-Masked, Multicenter Trial

Primary Endpoint: Proportion of subjects with change from baseline ≥ 15 letters in BCVA at Week 24



PEACHTREE: Take Home Points

Efficacy


- Primary endpoint was met, with ~47% of patients gaining ≥ 15 ETDRS letters
- Suprachoroidally injected CLS-TA significantly improved visual acuity and macular edema in all uveitis patients, regardless of the anatomic site of inflammation

Safety

- No SAEs attributable to CLS-TA
- Low rates of elevated IOP and cataract


PEACHTREE: Efficacy Endpoints

Primary Endpoint: Subjects gaining ≥ 15 BCVA letters from baseline, %





Intention-to-treat population; Last Observation Carried Forward imputation. The p-value is based on a Cochran-Mantel-Haenszel test for general association between treatment and response with stratification by country. t-test. Differences between the CLS-TA and control arms were significant at each visit. BCVA, best corrected visual acuity.

Mean Change in BCVA,
Mean Change in Central Subfield Thickness



Mean Change in BCVA by Uveitis Anatomic Location



● CLS-TA ● Control

Intention-to-treat population, last observation carried forward.

Safety

IOP-Related Events	CLS-TA 4.0 mg N = 96	Control N = 64
Elevated IOP adverse events	11 (11.5%)	10 (15.6%)
IOP elevation ≥ 10 mmHg change from baseline at any visit*	9 (9.4%)	7 (10.9%)
IOP elevation ≥ 30 mmHg absolute reading at any post baseline visit*	5 (5.2%)	4 (6.3%)
Given any additional IOP-lowering medication	7 (7.3%)	6 (9.4%)
Any surgical intervention for an elevated IOP Adverse Event	0	0

- One serious ocular AE
 - Retinal detachment 8 weeks after CLS-TA
 - Determined to be unrelated to study drug by the Investigator
- Cataract: 7.3% (7/96) in the CLS-TA arm vs. 6.3% (4/64) in the sham arm

Safety population; includes subjects in the control group who received rescue medication

*Based on elevated intraocular pressure adverse reactions